We recently isolated the r-PTPeta gene, which encodes a receptor-type tyrosine phosphatase protein that suppresses the neoplastic phenotype of retrovirally transformed rat thyroid cells. The human homologue gene PTPRJ/DEP-1 is deleted in various tumors. Moreover, the Gln276Pro polymorphism, located in the extracellular region of the gene, seems to play a critical role in susceptibility to some human neoplasias. Here we report the loss of heterozygosity (LOH) of PTPRJ in 11/76 (14.5%) informative thyroid tumors (including adenomas and carcinomas). We also looked for the Gln276Pro, Arg326Gln and Asp872Glu polymorphisms in exons 5, 6 and 13 of PTPRJ in 88 patients with thyroid tumors and in 54 healthy individuals. We found that the PTPRJ genotypes homozygous for the Gln276Pro and Arg326Gln polymorphisms, and the Asp872 allele were more frequent in thyroid carcinoma patients than in healthy individuals (P ¼ 0.032). In addition, PTPRJ LOH was more frequent in thyroid carcinomas of heterozygotes for Gln276Pro and Arg326Gln compared with homozygotes (P ¼ 0.006). This suggests that the presence of hemizygosity for these polymorphisms in the tumor facilitates tumor progression. These results indicate that the genotypic profile of PTPRJ affects susceptibility to thyroid carcinomas, and that allelic loss of this gene is involved in thyroid carcinogenesis.
Introduction
Follicular cell-derived thyroid tumors differ in their malignant potential: thyroid adenomas are benign, papillary and follicular differentiated carcinomas are rarely lethal, and anaplastic carcinomas are highly aggressive and undifferentiated (Hedinger et al., 1989) . Point mutations or rearrangements that lead to gain-offunction in oncogenes (e.g. ras, RET, TRK) and loss-offunction in tumor suppressor genes (e.g. p53) are involved in thyroid tumor formation (Gimm, 2001; Tallini, 2002) . In addition, overexpression of oncogenic proteins (e.g. c-Met, HMGA1) and downregulation of expression of tumor suppressor genes (e.g. PTEN, p27 kip1 ) play an important role in thyroid carcinogenesis (Di Renzo et al., 1992; Chiappetta et al., 1998; Baldassarre et al., 1999; Bruni et al., 2000; Gimm et al., 2000) .
Our group has isolated the r-PTPZ gene that encodes a receptor-type tyrosine phosphatase constituted by an extracellular region with eight fibronectin-like type III domains, a transmembrane domain, and an intracellular region with a single catalytic domain (Zhang et al., 1997) . Compelling evidence implicates r-PTPZ in thyroid tumor. Its expression is drastically reduced in rat thyroid cells transformed by acute murine retroviruses (Zhang et al., 1997) . Its re-expression in highly malignant rat thyroid cells transformed by retroviruses carrying the v-mos and v-ras-Ki oncogenes suppresses the malignant phenotype . Overexpression of r-PTPZ in malignant rat thyroid cells leads to increased p27 kip1 protein levels due to p27 kip1 protein stabilization that depends, in turn, on r-PTPZ-mediated inhibition of ERK1/2 . The in vitro growth of human thyroid cell lines and the tumor formation induced in athymic mice by injection of an anaplastic human thyroid cell line are inhibited by infection with a recombinant adenovirus carrying r-PTPZ (Iuliano et al., 2003) . Activation of r-PTPZ is required for the antiproliferative effect of somatostatin in rat thyroid cells (Florio et al., 2001) . The expression of receptor tyrosine phosphatase PTPRJ, the r-PTPZ human homologue, is lower in thyroid tumors than in normal thyroid tissues .
Tumor suppression by r-PTPZ is in line with the observation that overexpression of PTPRJ (also called DEP-1, HPTPZ and CD148) inhibits the growth of breast cancer cells (Keane et al., 1996) and its catalytic activity impairs the signaling of the growth factor receptors of PDGFb, VEGF and HGF (Kovalenko et al., 2000; Lampugnani et al., 2003; Palka et al., 2003) . PTPRJ has been associated with various human cancers. It is frequently deleted in human colon, lung and breast cancers (Ruivenkamp et al., 2002 (Ruivenkamp et al., , 2003 , and Gln276Pro, a PTPRJ polymorphism, has been implicated in susceptibility to human cancers (Ruivenkamp et al., 2002) . In addition, Ptprj was identified as the unique candidate gene for the mouse colon-cancer susceptibility locus Scc1 (Ruivenkamp et al., 2002) .
In an attempt to understand the effect of PTPRJ variants on human cancer, we evaluated PTPRJ genotypes and the frequency of PTPRJ genetic imbalance in thyroid tumors. Using loss of heterozygosity (LOH) analysis, we identified PTPRJ allelic imbalance in thyroid tumors and found a link between PTPRJ genotype and thyroid carcinogenesis. In particular, we show: (1) linkage between polymorphisms Gln276Pro and Arg326Gln; (2) a higher frequency of PTPRJ LOH in thyroid carcinomas of heterozygotes for Gln276Pro and Arg326Gln compared with homozygotes and (3) a higher frequency of the PTPRJ genotypes homozygotes for polymorphisms Gln276Pro and Arg326Gln and for allele Asp872 in thyroid carcinoma patients than in healthy individuals.
In conclusion, the data reported herein suggest that PTPRJ is a low-penetrance tumor-susceptibility gene in human thyroid carcinogenesis.
Results

LOH analysis
We analysed LOH at four microsatellite markers (D11S4117, D11S4183, D11S1784 and D11S1350) located in the PTPRJ genomic region in 88 DNA samples extracted from thyroid tumors (22 adenomas, 52 differentiated carcinomas and 14 anaplastic carcinomas) and their respective normal tissues. Twelve samples were excluded because they were not informative for LOH analysis at all the markers tested. We detected PTPRJ LOH in 14.5% (11 of 76) of the informative thyroid tumors at one or more polymorphic loci. Two examples of LOH are shown in Figure 1 . LOH was most frequent in anaplastic carcinomas (Table 1) , the LOH percentage was significantly higher in anaplastic than in differentiated carcinoma group (P ¼ 0.0089).
Analysis of variant frequencies
We analysed the sequences of exons 5, 6 and 13 of PTPRJ in normal DNA samples from the 88 tumor patients and from 54 healthy individuals (control group). These exons harbor three nucleotide polymorphisms, A1176C, G1326A and C2965G, which result in the coding polymorphisms Gln276Pro, Arg326Gln and Asp872Glu, respectively. Gln276Pro has been implicated in susceptibility to human cancers (Ruivenkamp et al., 2002) . The frequencies of the Gln276Pro and Arg326Gln PTPRJ variants in healthy individuals (0.78 for Gln276 and Arg326 alleles, 0.22 for Pro276 and Gln326 alleles), adenoma patients (0.73 for Gln276 and Arg326 alleles, 0.27 for Pro276 and Gln326 alleles) and carcinoma patients (0.81 for Gln276 and Arg326 alleles, 0.19 ;for Pro276 and Gln326 alleles) were quite similar. Conversely, the Asp872 variant was more frequent in thyroid carcinoma patients than in control group, but the difference was not statistically significant (Asp872 
Gln276Pro and Arg326Gln linkage
Sequence screening showed that homozygotes for the Gln276 allele were also homozygotes for the Arg326 allele, homozygotes for the Pro276 allele were also homozygotes for the Gln326 allele; the other individuals were heterozygotes for both polymorphisms. To verify linkage between Gln276Pro and Arg326Gln, we performed two types of experiments. In six heterozygous patients with PTPRJ LOH we sequenced also the DNA from the tumor sample, and found that in all cases the loss of the Gln276 allele was associated with the loss of the Arg326 allele, and that the loss of Pro276 allele was associated with the loss of the Gln326 allele. Two representative examples are shown in Figure 2a . The cDNA samples of two thyroid cell lines (BC-PAP and WRO), which were heterozygous for exons 5 and 6 alleles, were amplified by PCR using a forward primer upstream Gln276Pro and a reverse primer downstream Arg326Gln. The PCR products were cloned in pGEM-3T-easy vector and sequenced using T7 primer. Five clones for each cell line containing the amplified products were sequenced. In each clone, Gln276 was associated with the Arg326 allele or Pro276 with the Gln326 allele ( Figure 2b ). These results demonstrate that the alleles located in residues 276 and 326 segregate together. Table 2 shows the genotype frequencies for polymorphisms Gln276Pro, Arg326Gln and Asp872Glu. Homozygous genotypes for Asp872 were higher in patients with thyroid carcinomas than in the adenoma and control groups. There were fewer heterozygous individuals for Gln276Pro and Arg326Gln among thyroid carcinoma patients than among adenoma patients and controls. PTPRJ genotype distributions in the different groups had not significant departure from the HardyWeinberg equilibrium (Table 3) . Interestingly, in thyroid carcinoma group, the number of patients with a homozygous genotype for Asp872 variant was higher than expected and the number of homozygotes for Gln276Pro and Arg326Gln polymorphisms was higher than expected.
Analysis of genotype frequencies
PTPRJ LOH was significantly more frequent in carcinoma patients heterozygous for Gln276Pro and Arg326Gln than in homozygotes of the same group (P ¼ 0.006, Table 4 ). This result suggests that in thyroid tumor development, the loss of one PTPRJ allele is more important in heterozygotes than in homozygotes for Gln276Pro and Arg326Gln. Electropherograms of exons 5 and 6 sequences in normal and tumor tissues of two patients with LOH for PTPRJ. In patient 1, the loss in exon 5 of codon CAA encoding Gln is associated with the loss in exon 6 of codon CGA encoding Arg. In patient 2, the loss in exon 5 of codon CCA encoding Pro is associated with the loss in exon 6 of codon CAA encoding Gln (a). Electropherograms of two examples of exons 5 and 6 sequences in clones derived from cDNA of cell lines heterozygous for the Gln276Pro and Arg326Gln polymorphisms. In clone 1 at the sequence of exon 5 encoding Gln276 corresponds the sequence of exon 6 encoding Arg326. In clone 2 at the sequence of exon 5 encoding Pro276 corresponds the sequence of exon 6 encoding Gln326 (b) In the thyroid carcinoma group we found five patients heterozygotes for Asp872Glu polymorphism with LOH of PTPRJ. In four of them the Asp872 variant was retained, suggesting again that this allele is associated with thyroid tumor progression.
These results prompted us to calculate the frequency of PTPRJ genotypes homozygous for Gln276Pro and Arg326Gln polymorphisms and homozygous for the Asp872 variant in the carcinoma patients and the healthy individuals. We found that PTPRJ genotypes homozygous for Gln276Pro and Arg326Gln polymorphisms and homozygous for the Asp872 variant were significantly more frequent in thyroid carcinoma patients than in healthy individuals (P ¼ 0.032, Table 5 ). Therefore, this PTPRJ genotype seems to be preferentially associated with thyroid carcinoma, and might hence increase susceptibility to thyroid cancer development.
PTPRJ polymorphisms in human thyroid cell lines
We analysed nine human carcinoma thyroid cell lines for the PTPRJ polymorphisms and only two were heterozygous for the Gln276Pro and Arg326Gln polymorphisms (Table 6 ). In addition, the BC-PAP cell line that was heterozygous for Pro276Gln and Gln326Arg expresses only the allele carrying the Pro276 and Gln326 codons (data not shown). Asp872 occurred more frequently than Glu872 in the cell lines analysed. Three cell lines were homozygous for the Asp872 variant and only one for the Glu872 variant. We also analysed the PTPRJ genotype in four thyroid hybrid cell lines that have a malignant potential lower than their parental cell lines (Martelli et al., 2000) . In all hybrid cell lines, there was acquisition of heterozygosity for Gln276Pro and Arg326Gln and/or acquisition of Glu872, which might represent a more favorable genotype than one or both parental cell lines.
These data confirm the importance of the PTPRJ genotypic profile in thyroid carcinogenesis.
Discussion
The gene encoding the receptor-type tyrosine phosphatase PTPRJ is a candidate tumor suppressor gene located in the 11p11 region of the human genome. Allelic imbalance of PTPRJ has been found in various human cancers (Ruivenkamp et al., 2002 (Ruivenkamp et al., , 2003 and both the human and rat forms inhibit cell growth and the tumorigenicity of various cell types (Keane et al., 1996; Trapasso et al., 2000; Iuliano et al., 2003; Lampugnani et al., 2003) . Several coding polymorphisms have been detected in the PTPRJ sequence and they may affect gene function (Ruivenkamp et al., 2002) . The expected number was calculated using the Hardy-Weinberg law In this study, we determined the frequency of LOH events in PTPRJ in a panel of thyroid tumors, and the allele and genotype frequency of three coding polymorphisms in the same tumors and in healthy individuals. PTPRJ LOH occurred in about 14% of thyroid tumors overall, and in 38% of the anaplastic carcinomas, which are the most malignant of thyroid tumors. Interestingly, allelic imbalance has previously been described in the 11p region where PTPRJ is located, and consistent with our results, the frequency of LOH was higher in anaplastic carcinomas than in differentiated carcinomas (Kitamura et al., 2001) . Mice lacking Ptprj die during gestation . However, Ptprj heterozygous knockout mice are viable and can be used to investigate the relevance of the loss of one Ptprj copy in carcinogenesis.
We analysed the sequences of PTPRJ exons 5, 6 and 13 to determine the allele frequencies of the Gln276Pro, Arg326Gln and Asp872Glu polymorphisms. They are located in the extracellular region of the phosphatase and contribute to the formation of fibronectin-like type III domains (Ruivenkamp et al., 2002) . There were no differences in the allele frequencies of Gln276Pro and Arg326Gln between carcinoma patients, adenoma patients and control individuals. On the contrary, the Asp872 allele and its relative homozygous genotype were more frequent in patients with thyroid carcinomas than in healthy individuals. It has been demonstrated that dimerization inactivates the receptor-type phosphatases CD45 and RPTPa (Bilwes et al., 1996 , Majeti et al., 1998 and the region around the transmembrane domain is fundamental for this process (Jiang et al., 2000) . A similar mechanism may regulate PTPRJ activity. Should this be the case, an aspartate residue instead of glutamate at codon 872, which is in an exposed position near the transmembrane domain (Ruivenkamp et al., 2002) , would facilitate dimerization-induced PTPRJ inactivation. In fact, the lateral chain of aspartate is shorter than that of glutamate thus reducing the effects of opposite negative charges. This model could be verified in crystallographic and functional studies.
Genotype analysis revealed that Gln276Pro and Arg326Gln polymorphisms segregate together. Interestingly, both codons contribute to the formation of the second fibronectin-like type III domain and the resulting two allelic forms have different charge and folding characteristics (Ruivenkamp et al., 2002) . Fewer carcinoma patients were heterozygous for the Gln276Pro and Arg326Gln polymorphisms compared with adenoma patients and controls. Moreover, we should recall that LOH occurred more frequently in heterozygous patients so leading to hemizygosity in the tumor. Thus, these data suggest that the presence of a single PTPRJ allele for polymorphisms Gln276Pro and Gln326Arg, consequent to the homozygous or hemizygous status, increases the probability of malignant tumor thyroid formation. Whether this is a general event in carcinogenesis or whether it is restricted to thyroid cancer remains to be clarified. We did not find a PTPRJ variant preferentially retained in tumor samples with LOH, whereas a particular PTPRJ variant may exert inhibitory action in other cancer types. In fact, in human colorectal carcinomas with PTPRJ LOH, the Gln276 allele is preferentially lost (Ruivenkamp et al., 2002) .
Increased homozygosity in two linked polymorphisms of TRAIL receptor DR4, a gene encoding a protein that has apoptotic activity (Bodmer et al., 2000) , has been found in patients with lung cancer, and head and neck cancer (Fisher et al., 2001) . The polymorphisms involved are located in the ectodomain of DR4 and probably disrupt interaction with the ligand thereby impairing protein function (Fisher et al., 2001) . A similar mechanism could be evoked for the PTPRJ Gln276Pro and Arg326Gln polymorphisms. As yet, no ligands of the PTPRJ protein have been identified, but it has been demonstrated that matrigel contains molecules able to increase the enzymatic activity of PTPRJ (Sorby et al., 2001) . The products of different PTPRJ alleles may have diverse affinities for putative ligands and heterozygotes could respond to external stimuli with a higher efficiency than homozygotes. Alternatively, if PTPRJ is regulated by ligand-dependent dimerization, the heterodimers may have a lower affinity for the ligand thus impairing dimerization-induced phosphatase inactivation. These speculations need to be addressed in functional studies.
The simultaneous analysis of the Gln276Pro, Arg326Gln and Asp872Glu polymorphisms revealed that the frequency of the PTPRJ genotype homozygous for the Gln276Pro and Arg326Gln polymorphisms and homozygous for the Asp872 allele is significantly higher in thyroid carcinoma patients than in healthy individuals. The statistical significance of this analysis indicates that the Gln276Pro, Arg326Gln and Asp872Glu polymorphisms contribute all together to the generation of the PTPRJ genotyp associated with patients affected by thyroid tumor.
The PTPRJ genotypic profile in human thyroid carcinoma cell lines confirms our data obtained in human samples, although tumor cell lines are not always good models of their in vivo counterparts (Dumont et al., 2002) . The Asp872 allele was more frequent than the Glu872 allele and only two of nine thyroid cell lines were heterozygous for Gln276Pro and Arg326Gln polymorphisms. Moreover, the thyroid hybrid cell lines analysed displayed a more favorable PTPRJ genotype compared with their more malignant parental cell lines.
In conclusion, the data reported here suggest that PTPRJ is a low-penetrance tumor-susceptibility gene in human thyroid carcinogenesis.
Materials and methods
Patients and cell lines
Twenty-two patients with thyroid adenomas, mainly toxic adenomas, 52 patients with differentiated thyroid carcinomas, mainly papillary, and 14 patients with thyroid anaplastic carcinomas were enrolled in the study. Fifty-four blood donors served as controls. Patients and controls were from Lyon, Naples and Catanzaro. Slides containing follicular thyroid cells were stained with hematoxylin-eosin and reviewed by an expert pathologist for confirmation of the diagnosis of thyroid tumors.
The five cell lines derived from human papillary thyroid carcinomas (BC-PAP, NIM, NPA, FB2 and TPC-1), one cell line from a follicular thyroid carcinoma (WRO), three cell lines from anaplastic thyroid carcinomas (ARO, FRO and FB1) and four thyroid hybrid cell lines (WRO-NPA, WRO-FRO, WRO-ARO and FRO-NIM) used in this study are described elsewhere (Cerutti et al., 1996; Fiore et al., 1997; Martelli et al., 2000; Basolo et al., 2002) .
LOH analysis
Four microsatellite markers located in PTPRJ genomic region (11p11) were used for LOH analysis. D11S4117 is located telomeric to PTPRJ and is closely linked to exon 1, D11S4183 and D11S1784 are located in intron 1 and D11S1350 in intron 21 (Ruivenkamp et al., 2002) . Paired DNA genomic samples were extracted from normal and tumor tissues with the DNA extraction kit (Promega). DNA samples were amplified by PCR using specific primers labeled with 6-FAM fluorescent dye. Oligonucleotide sequences were accessed from http:// www.ncbi.nlm.nih.gov in the UniSTS database (accession numbers: Z52746, Z53978, Z52254 and Z243941 for the microsatellites D11S4117, D11S4183, D11S1784 and D11S1350, respectively). Genomic DNA samples of 100-200 ng were subjected to PCR in 15 ml aliquots containing 5 pmol of each primer, 1 Â reaction buffer (PE Applied Biosystems), 2.5 mM MgCl 2 , 250 mM dNTPs and 0.6 U (or 2 U for D11S1350) of Taq Gold DNA polymerase (PE Applied Biosystems). PCR reactions were carried out as follows: initial denaturation step of 941C for 10 min, followed by 35 cycles of 30 00 at 941C (or 20 00 for D11S4117 and D11S1784), 30 00 at 581C (or 20 00 at 621C for D11S4117 and D11S1784), 40 00 at 721C (or 30 00 for D11S4117 and D11S1784), and a final step of extension at 721C for 7 min. Electrophoresis on a 2% agarose gel was performed to verify the amplification. PCR products were diluted 1 : 20, denatured at 941C for 5 min in a buffer containing formamide, run on a 3100 Automated Sequencer and analysed using the Genescan Analysis 3.7 (Applied Biosystems). A difference of 30% or more in the intensity ratio of the two alleles in tumor DNA compared with normal DNA was considered evidence for LOH.
Sequence analysis
Genomic DNA samples were amplified by PCR using specific primers. Oligonucleotide sequences were: 5 0 -GAAGGT GACTGCATATATCT-3 0 (exon 5 forward), 5 0 -AGAACATT TAGTTACTGAAAG-3 0 (exon 5 reverse), 5 0 -CCTCTTGT GGTTGATGTCTT-3 0 (exon 6 forward), 5 0 -CCCCTATTAT CAAAGTTCAAC-3 0 (exon 6 reverse), 5 0 -CTGCCATCAC TTTCTTATGAT-3 0 (exon 13 forward), 5 0 -CCCAAAGAG TAAGAACCAGA-3 0 (exon 13 reverse). Genomic DNA samples of 100-200 ng were subjected to PCR in 50 ml aliquots containing 25 pmol of each primer, 1 Â reaction buffer (PE Applied Biosystems), 1.5 mM MgCl 2 (or 2.5 mM for exon 6), 400 mM dNTPs and 2 U of Taq Gold DNA polymerase (PE Applied Biosystems). PCR reactions were carried out as follows: initial denaturation step of 941C for 10 min, followed by 40 cycles of 40 00 at 941C, 40 00 at 561C (or 551C for exon 5), 1 min at 721C, and a final step of extension at 721C for 7 min. Electrophoresis on a 2% agarose gel served to verify amplification. PCR products were directly sequenced in both strands using the same primers and Big Dye Terminators in a 3100 Automated Sequencer (Applied Biosystems).
Specific allele expression
Total RNA samples (2-3 mg) were used to synthesize cDNAs using random primers and AMV reverse transcriptase with the reverse transcriptase kit (Promega) following the manufacturer's instructions. The cDNAs were amplified using two primers located in exons 5 and 6 (5 0 -CGATCCCAGTTTCT GAT-3 0 exon 5 forward, 5 0 -TTCTGTGCCATTCGCTGC-3 0 exon 6 reverse). Two microliters of cDNA samples were subjected to PCR in 50 ml aliquots containing 25 pmol of each primer, 1 Â reaction buffer (PE Applied Biosystems), 1.5 mM MgCl 2 , 400 mM dNTPs and 2 U of Taq Gold DNA polymerase (PE Applied Biosystems). PCR reactions were carried out with the following conditions: initial denaturation step of 941C for 10 min, followed by 40 cycles of 40 00 at 941C, 40 00 at 551C, 1 min at 721C, and a final step of extension at 721C for 7 min. Electrophoresis on a 2% agarose gel was used to verify the amplification. PCR products were purified with a PCR purification kit (Qiagen) and ligated in pGEM-T-easy vector following the manufacturer's instructions (Promega). The products of ligation reaction were used to transform competent cells of Escherichia coli strain JM101. Independent clones were harvested after ampicillin selection and the recombinant plasmids contained in the clones were extracted and sequenced using the universal T7 primer and Big Dye Terminators in a 3100 Automated Sequencer (Applied Biosystems).
Statistical analysis
To compare the allele or genotype frequencies among groups, we used two-tailed either Pearson's w 2 test or Fisher's exact test, depending on which was more appropriate. Significance was set at Po 0.05.
